What does this research mean for the field?

The future management of hemophilia A will rely on 'Precision Coagulation', a framework utilizing non-biologic therapies to modulate endogenous hemostatic pathways rather than traditional factor replacement. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.ESTABLISHES_NEW_DIRECTION.

What question did this study set out to answer?

To review the evolving role of non-biologic therapies in hemophilia A and propose a biomarker-driven precision coagulation framework for individualized treatment.

September 14, 2026Expert Opinion on Pharmacotherapy

Future management of hemophilia a with non-biologic hemostatic agents: a call for precision coagulation

View Full Paper

Ask AI

Bookmark

Authors

JMJohnny MahlanguNational Health Laboratory Service

Discussion

Member takes

Implication

Narrative review demonstrates the potential of non-biologic agents to rebalance clotting pathways in hemophilia A, indicating a shift toward individualized precision coagulation.

Key Points

To review the evolving role of non-biologic therapies in hemophilia A and propose a biomarker-driven precision coagulation framework for individualized treatment.
Searched PubMed/MEDLINE, Embase, ClinicalTrials.gov, major conference proceedings, and regulatory guidance sources.
Synthesized evidence on non-biologic modalities, including RNA therapeutics and emerging oral small molecules that rebalance endogenous hemostasis.
Demonstrated that non-biologic modalities can restore hemostatic equilibrium by modulating endogenous coagulation pathways without requiring factor VIII replacement.
Defined Precision Coagulation as an integrative framework combining clinical features, laboratory assays, pharmacodynamics, and biomarkers to guide personalized care.

Cite This Study

Johnny Mahlangu (2026) studied this question.

synapsesocial.com/papers/6aa7b3aa0926e14a848b2d75 https://doi.org/10.1080/14656566.2026.2734120

View Full Paper

Ask AI

Bookmark

Implication

Narrative review demonstrates the potential of non-biologic agents to rebalance clotting pathways in hemophilia A, indicating a shift toward individualized precision coagulation.

Future management of hemophilia a with non-biologic hemostatic agents: a call for precision coagulation

Discussion

Member takes

Implication

Key Points

Cite This Study

Future management of hemophilia a with non-biologic hemostatic agents: a call for precision coagulation

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider